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Abstract. Tuberculosis (TB) remains the leading cause of hospitalization and in-hospital mortality in HIV-positive
adults. Using data from hospital and clinic files, research databases, and autopsy, we describe causes and outcomes of
admissions, and assess investigations for TB among adults with advanced HIV who were hospitalized after enrollment
into the TB Fast Track trial in South Africa (2013–2015). A total of 251 adults [median CD4 count, 37.5 cells/mL; interquar-
tile range, 14–68 cells/mL; 152 (60.6%) on antiretroviral therapy] experienced 304 admissions. Ninety-five of 251 of the
first admissions (37.8%) were TB related; the next most common causes were AIDS-related illnesses (41 of 251, 16.3%)
and surgical causes (21 of 251, 8.4%). Of those admitted with previously undiagnosed TB, 60% had CD4 counts less
than 50 cells/mL. Overall, 137 of 251 individuals died as inpatients or within 90 days of their first discharge. Case fatality
rates were particularly high for those admitted with TB (66%) and bacterial infections (80%). In 144 admissions for whom
anti-TB treatment had not been started before admission, a sputum-based TB investigation was recorded in only 12 of
57 admissions (21.1%) in whom one or more TB symptom was recorded (24 of 57 started on treatment), and 6 of 87
admissions (6.9%) in whom no TB symptoms were recorded (14 of 87 started on treatment). Hospitalized adults with
advanced HIV are at high risk of death. TB was a common cause of hospitalization but was under-investigated, even in
those with symptoms. In addition to early identification of TB and other AIDS-related illnesses during hospitalization of
adults with advanced HIV, improved pre-hospital management strategies are needed to interrupt disease progression
and reduce poor outcomes in this already vulnerable population.
INTRODUCTION
Despite increased availability of antiretroviral therapy
(ART), adults with advanced HIV (CD4 count,, 200 cells/mL,
or WHO clinical stage 3 or 4 at presentation)1 are at high risk
of poor outcomes.2 Mortality in hospitalized adults with
advanced HIV in sub-Saharan Africa ranges from 7% to
44%,3–7 and 25% to 40% of adults initiated on ART in low-
and middle-income countries have advanced HIV at the time
of initiation.8 It is therefore critical to understand the reasons
for continued poor outcomes in this vulnerable group, but
this is not straightforward, as routine data on morbidity
and mortality in individuals with advanced HIV are not
widely available in most countries most affected by the HIV
epidemic.
The WHO recommends timely ART initiation and early
management of opportunistic infections as part of an inte-
grated package of care for individuals with advanced HIV.1
An important diagnostic element of this package is to test
sputum for tuberculosis (TB) using the Xpert MTB/RIF assay
for all symptomatic adults,9 and to test urine using lateral-
flow lipoarabinomannan (LF-LAM) in adults with CD4 counts
less than 100 cells/mL. This is necessary because TB
remains the leading cause of hospitalization and in-hospital
mortality in HIV-positive adults worldwide,10 and autopsy
studies show that around 50% of TB goes undiagnosed in
hospitalized HIV-positive individuals.11,12
Screening HIV-positive adults for TB using the WHO four
clinical symptoms (current cough, fever, night sweats, or
weight loss) is 78.9% (95% CI, 58–91%) sensitive.13 How-
ever, the negative predictive value is lower in settings with
a greater TB prevalence.13 In two studies in South Africa,
Lawn et al.14,15 demonstrated that symptoms were not
predictive for TB in adults admitted to the hospital, sug-
gesting a need for routine TB testing for all HIV-positive
adults admitted to medical wards in high TB-burden set-
tings, regardless of presenting complaints.14,16 Although
LF-LAM has been recommended for use,17 it has not yet
been implemented routinely in hospitals in South Africa.
Therefore, it remains relevant to develop our understanding
more fully regarding the utility of sputum investigations in
adults with advanced HIV.
We aimed to estimate the causes and outcomes of
admission, and assess the investigation and treatment of
TB during admission, of the ambulatory adults with
advanced HIV who were recruited to the TB Fast Track trial
at 24 primary health-care (PHC) clinics in South Africa and
were subsequently admitted to the hospital between 2013
and 2015.18
METHODS
Parent trial. Our analysis used data from adults with
advanced HIV who were admitted to the hospital up to 1
year after enrollment to TB Fast Track—a pragmatic, cluster-
randomized trial of empirical TB treatment of patients
attending PHC clinics in South Africa. Detailed trial methods
have been reported previously.18,19 In brief, HIV-positive
adults were recruited to TB Fast Track at 24 PHC clinics; 12
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clinics were allocated randomly to each of the intervention
and control arms. Participants were 18 years or older, with
CD4 counts of#150 cells/mL, and had not received TB treat-
ment or ART in the previous 3 or 6 months, respectively. In
the intervention arm, each participant was assessed for their
probability of active TB using the study algorithm and was
initiated on empirical TB treatment as soon as possible if
considered “high probability.” Participants in the control arm
were managed by clinic staff in line with their usual practi-
ces. There were seven public referral hospitals surrounding
the 24 PHCs. Inpatient management was not part of the
intervention, and the study team did not capture admissions
in real time or influence the management of hospitalized
participants.
Context. The Xpert MTB/RIF assay was rolled out in
South Africa from 2011 to 2013 as the first-line TB diagnos-
tic test. At the time of the study (and still today), national
guidelines recommended an Xpert MTB/RIF on sputum for
all individuals with symptoms suggestive of TB.20 In HIV-
positive adults, a chest radiograph, second sputum for cul-
ture, and course of antibiotics are suggested if the initial
Xpert MTB/RIF is negative.21 Urine LF-LAM had not been
recommended for hospitalized adults with advanced HIV at
the time of the study and has not yet been implemented in
hospitals in South Africa. Patients were referred from PHC
facilities to district or tertiary level hospitals when inpatient
management was needed.
Notification of hospitalization and collection of data
from hospitals and laboratories. All participants were
asked by study staff at follow-up visits if they had attended a
hospital at any point after enrollment. Study staff also
looked for evidence of hospitalizations when abstracting
data from clinic files. For each participant with a recorded
hospitalization and for all participants who were recorded
as having died after enrollment, the study team searched
the admission records manually of the surrounding public
hospitals and reviewed clinical notes when they could be
located. The National Health Laboratory Service (NHLS)
database was also searched and the results of investiga-
tions recorded. Data were abstracted by a member of the
study team (doctor or professional nurse) using standard-
ized paper forms. Ascertainment of death was done as
part of the main trial and has been described previously
in detail.18
Data management. Records of participants’ hospitaliza-
tion were maintained in a password-protected Microsoft
Excel workbook (Version 2108, Microsoft Corporation, Red-
mond, WA). Anonymized data from hospital files and the
NHLS database were maintained in EpiData databases (Epi-
Data Association, Odense, Denmark). Relevant data from
the parent trial and an autopsy sub-study were also used to
inform the analysis.22 The data are available at https://
datacompass.lshtm.ac.uk/.
Analysis. Inclusion and exclusion criteria. An admission
was defined as spending at least one night in a hospital or
death in a hospital on the day of attendance. Admissions
from both trial arms that occurred from enrollment up to 1
year after enrollment were included. Characteristics of
admissions were only assessed for individuals’ first admis-
sion. Data from individuals not on TB treatment at the time
of admission (from either study arm) were used to assess the
extent of investigation for TB during admission.
Research-assigned cause of admissions. For each
recorded admission, the most likely cause of admission was
assigned by a research physician (P. G. B.) using all the
available information. This included information that was not
available to clinicians assessing the individual in real time,
such as information from PHC clinic files, results of labora-
tory tests conducted in other facilities, and findings from the
parent trial or mortality sub-study (e.g., urine LF-LAM results
or autopsy findings). Research-assigned causes were classi-
fied into mutually exclusive categories (Table 1), with criteria
pre-specified for likelihood of diagnosis (possible, probable,
or definite) using a standardized tool (Supplemental Table
S1). System-based categories were used (renal/liver failure,
and hematological, neurological, and gastrointestinal disor-
ders) when information was insufficient to assign a more
specific diagnosis.
A random sample of 20% of admissions were reviewed
independently by another research physician (A. S. K.) to val-
idate the initial research assignments. Comparison was
made between causes assigned by the two reviewers, and
Cohen’s k was used to estimate inter-rater agreement. A pri-
ori, a k value of $ 0.60 was considered sufficient for 1) no
further validation to be conducted and 2) for the causes
assigned by the primary research physician to be used for
analysis.
Investigation of TB and treatment of TB and HIV in adults.
Evidence for the investigation of TB was sought from hospi-
tal notes and NHLS data for admissions when the individual
was not on TB treatment at the point of admission. Investi-
gations assessed were those suggested in national guide-
lines20—namely, Xpert MTB/RIF, chest radiographs, sputum
microscopy, and mycobacterial blood and sputum cultures.
Individuals were considered to have TB symptoms if they
were recorded to have any of the four WHO screening
symptoms at admission.23 Of the individuals started on TB
treatment during admission, evidence was sought for bacte-
riological confirmation of TB. Treatment charts and notes
were assessed to determine how many individuals were initi-
ated on ART during admission and how many were referred
to their primary-level clinic to be initiated on treatment
post-discharge.
Analysis. Anonymized data sets were merged by partici-
pant identification numbers; analysis was done using Stata
v15 (Stata Corp., College Station, TX). For individuals with
multiple admissions, data from the first admission after
enrollment were used for analysis.
Ethical considerations. The parent trial received ethical
approval from the research ethics committees of the Univer-
sity of the Witwatersrand, the London School of Hygiene &
Tropical Medicine, the South African Medicine Controls
Council, and provincial and district departments of health.
This analysis was approved by the London School of
Hygiene & Tropical Medicine. All participants gave informed
consent, which included permission for the study team to
extract information from clinical and laboratory records. No
identifiers were extracted from hospital files.
RESULTS
Demographics. A total 3,022 individuals with advanced
HIV were enrolled to the TB Fast track trial (1,507 in the inter-
vention arm and 1,515 in the control arm). Overall, 285 adults
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had recorded hospital admissions; 34 individuals were
excluded from the analysis as the admission occurred
outside the specified time (Figure 1). The remaining 251 indi-
viduals [130, or 51.8%, female; median age, 38.8 years;
interquartile range (IQR), 32.9–45.1 years; Table 2] experi-
enced 304 admissions from January 2013 to September
2015 (37 individuals had more than one admission); 106
(34.9%) admissions were identified through the study team
being notified and the remainder were ascertained because
the individual was recorded as having died. The median
time from trial enrollment to an individual’s first admission
was 40 days (IQR, 14–124 days) and the median length of
admission was 5 days (IQR, 2–10.5 days). A total of 101 of
145 individuals (69.7%) in the intervention arm were on TB
treatment at the time of their first admission, compared
with 25 of 106 individuals (23.6%) in the control arm.
Although 152 of 251 individuals (60.6%) were on ART at the
time of their first admission, CD4 counts at admission were
less than 150 cells/mL for 108 of 114 individuals (94.7%) with
a recorded result (median, 37.5 cells/mL; IQR, 14–68
cells/mL).
Research-assigned causes of admission. Inter-rater
agreement was acceptable (k value, 0.65; 95% CI,
0.51–0.79) and causes of admission assigned by the primary
research physician were used for analysis (Supplemental
Table S2). TB was the most commonly assigned cause of
first admission. Ninety-five of 251 individuals (37.8%) were
admitted with TB [52 of 251 (20.7%) with “previously undiag-
nosed TB” and 43 of 251 (17.1%) with “on TB treatment with
worsening TB disease”] (Table 3). “Definite” evidence was
found for 20 of 95 (21.1%) TB-related admissions. The next
most common research-assigned causes of first admission
were AIDS-related illnesses (n541, 16.3%; Supplemental
Table S3), surgical causes (n521, 8.4%), and bacterial
infections (n520, 8.0%). Participant characteristics cross-
referenced with research-assigned causes of admission are
shown in Table 4, and a full list of participant characteristics
with assigned causes and outcomes is provided in Supple-
mental Table S2. In subsequent admissions (second, third,
and fourth admissions), AIDS-related illness was the most
common research-assigned cause [14 of 53 (26.2%) admis-
sions], followed by “on TB treatment with worsening TB dis-
ease” (n59, 17.0%) and “surgical conditions” (n 5 8,
15.1%; Supplemental Table S4).
Unsurprisingly, given the nature of the intervention, more
participants in the control arm than the intervention arm of
TB Fast Track were assigned a “previously undiagnosed TB”
admission cause (control: 38 of 128, 29.7%; intervention: 17
of 176, 9.7%), and more individuals in the intervention arm
than the control arm were assigned a “worsening TB disease
on TB treatment” admission cause (control: 17 of 128,
13.3%; intervention: 35 of 176, 19.9%). Ninety-one partici-
pants enrolled to the TB Fast Track intervention group who
were assessed to have a high probability of TB based on the
trial’s algorithm (LF-LAM positive, hemoglobin , 10 g/dL, or
body mass index , 18.5 kg/m2) were admitted. Twenty-five
of 91 participants (27.5%) were assigned a cause of
“worsening TB disease on TB treatment” and 18 of 91 par-
ticipants (19.8%) were assigned a cause of “AIDS-related ill-
ness” (Supplemental Table S5).
TABLE 1
Categories for causes of admission based on prespecified criteria for likelihood of diagnosis*
Category of causes Description of category
Previously undiagnosed TB In individuals not on TB treatment at the point of admission with
clinicopathological features in keeping with TB, with or without
microbiological confirmation, and regardless of whether TB treatment was
initiated during admission.
Prespecified likelihood of diagnosis allocated to each ‘Previously
undiagnosed TB’ admission:
 Definite: microbiological evidence for TB (positive Xpert MTB/RIF assay
or positive TB culture)
 Probable: positive AFB microscopy; positive urine LAM; or CSF, chest
X-ray, or ultrasound features in keeping with TB
 Possible: clinicopathological features of TB
On TB treatment with worsening TB disease In individuals on TB treatment admitted as a result of worsening TB disease
Bacterial infections Admissions resulting from bacterial infections based on clinicopathological
evidence for a bacterial infection, including microbiological isolation of an
organism or investigation findings specific to bacterial infections. This
category excludes new TB cases and surgical-related infections.
AIDS-related illnesses Admissions secondary to WHO clinical stage IV diagnoses,38 excluding TB
and severe bacterial infections
Treatment-related conditions Admissions resulting from treatment side effects
Non-communicable diseases Admissions resulting from cardiovascular diseases, diabetes, cancer
(excluding AIDS-related cancers), and chronic respiratory diseases
Surgical conditions Any surgical condition not related to another category
Psychiatric conditions All psychiatric conditions
Renal/liver failure All forms of renal failure and liver failure not fitting into the previous categories
Hematological disorders Hematological conditions that do not fit into other categories
Neurological disorders Neurological conditions that do not fit into other categories
Gastrointestinal disorder Any gastrointestinal disorder that does not fit into other categories. This group
included acute gastroenteritis with no underlying diagnosis.
Unknown Any admission for which there was not enough recorded information in the
case report form to place into any other category
AFB5 acid-fast bacilli; CSF5 cerebrospinal fluid; LAM5 lipoarabinomannan; TB5 tuberculosis.
* See Supplemental Table S1 for criteria used to assign each cause of admission.
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Outcomes of admissions. Ninety-eight of 251 individuals
(39.0%) died in the hospital during their first admission; 151
of 251 individuals (60.2%) were discharged home (two
individuals were transferred to different facilities and the out-
comes are unknown). Of the 151 who were discharged, 39
(25.8%) died within 90 days of discharge and 19 (12.6%)
3022 individuals enrolled into
TB Fast Track  trial
1515 on control arm 
1507 on the intervenon arm
323 individuals had hospital visits 
251 individuals were admied from 
enrolment to one year post-enrolment
(January 2013 to September 2015)
Individuals excluded from analysis:
1. 39 individuals had hospital visits that did not 
meet the definion for an admission
2. 23 individuals had admissions that occurred 
before enrolment to TB Fast Track
3. 10 individuals had admissions that occurred 
one year aer enrolment to TB Fast Track 
304 admissions in total:
214 individuals had 1 admission; 
27 individuals had 2 admissions;
5 individuals with 3 admissions; 
4 individuals with 4 admissions; 
1 individual with 5 admissions
145 individuals in the intervenon arm 
of TB Fast Track of whom 101 were on 
TB treatment at first admission 
106 individuals in the control arm of TB 
Fast Track of whom 25 were on TB 
treatment at first admission
176 admissions
(17 individuals had >1 admission)
128 admissions 
(20 individuals had >1 admission)  
FIGURE 1. Flow diagram showing numbers of participants enrolled in the TB Fast Track trial, admitted to the hospital, included and excluded
from analysis (with reasons), and the numbers of admissions recorded by study arm. TB5 tuberculosis.
TABLE 2
Demographics of individuals (N5251) at their first admission and by TB Fast Track trial arm
Characteristic
All individuals (N5251), n (%)
or median (IQR)
Individuals in TBFT intervention arm
(n5 145), n (%) or median (IQR)
Individuals in TBFT control arm
(n5106), n (%) or median (IQR)
Female 130 (51.8) 78 (53.8) 52 (49.1)
Age (y) 38.8 (32.9–45.1) 39.3 (33.0–47.0) 37.8 (32.9–42.7)
Province
Gauteng 192 (76.5) 113 (77.9) 79 (74.5)
Limpopo 37 (14.7) 23 (15.9) 14 (13.2)
North-West 22 (8.8) 9 (6.2) 13 (12.3)
Level of hospital admitted to
District 238 (94.8) 142 (97.9) 96 (90.6)
Tertiary 13 (5.2) 3 (2.1) 10 (9.4)
On ART* 152 (60.6) 74 (51.0) 78 (73.6)
On TB treatment 126 (50.2) 101 (69.7) 25 (23.6)
Previous TB† 33 (13.2) 18 (12.4) 15 (14.2)
CD4 count at admission (cells/mL)
, 50 67 (58.8)‡ 39 (59.1)§ 28 (58.3)|
50–100 37 (32.5) 22 (33.3) 15 (31.3)
100–150 4 (3.5) 2 (3.0) 2 (4.2)
.150 6 (5.3) 3 (4.6) 3 (6.3)
Serum hemoglobin (g/dL) 9.2 (7.2–11.3)¶ 9.2 (7.3–11.3)# 9.2 (7.2–11.4)**
Creatinine (mmol/L) 88 (65–226)†† 89 (66–189)‡‡ 85.5 (65–326)§§
ART5 antiretroviral treatment; GFR5glomerular filtration rate; IQR5 interquartile range; TB5 tuberculosis; TBFT5TB Fast Track trial.
* Three individuals did not have recorded ART status.
†Previous TB prior to enrollment to the TB Fast Track trial.
‡One hundred fourteen individuals had CD4 counts available at admission.
§Sixty-six individuals in the intervention arm had CD4 counts available at admission.
kForty-eight individuals in the control arm had CD4 counts available at admission.
¶A total of 223 individuals had a serum hemoglobin level at the time of admission.
#A total of 127 individuals in the intervention arm had a hemoglobin level at the time of admission.
**Ninety-six individuals in the control arm had a hemoglobin level at the time of admission.
††A total of 206 individuals had a creatinine level at the time of admission
‡‡A total of 114 individuals in the intervention arm had a creatinine level at the time of admission.
§§Ninety-two individuals in the control arm had a creatinine level at the time of admission.
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were readmitted to hospital within 30 days of discharge
(Supplemental Table S6). Fifteen individuals died during sub-
sequent admissions, bringing overall in-patient mortality to
113 of 251 (45.0%). A total 137 of 251 individuals (54.6%)
died in the hospital or 90 days after discharge from their first
admission (Figure 2). Of the 95 individuals with a research-
assigned TB-related cause of first admission, 50 (52.6%)
died during admission and a further 13 (13.7%) died within
90 days post-discharge. Of the 52 individuals assigned a
“previously undiagnosed TB” cause of admission, 12 of 22
(54.5%) who did not receive anti-TB treatment died in the
hospital, and 15 of 30 individuals (50.0%) who did receive
anti-TB treatment died as inpatients.
TB symptoms and investigation for TB. Of the total 304
admissions, 144 (47.4%) occurred in individuals who were
not on anti-TB treatment at the point of admission; recorded
TB symptoms, investigations, and treatment were examined
in these 144 admissions (Figure 3). At least one TB symptom
was recorded in 57 of 144 admissions (39.6%): cough in 43
of 144 (29.9%), weight loss in 28 of 144 (19.4%), fever in 21
of 144 (14.6%) and night sweats in 14 of 144 (9.7%). At least
one investigation for TB was conducted in 64 of 144 admis-
sions (44.4%); a sputum sample was collected in 18 of 144
individuals (12.5%) and a chest radiograph was conducted
in 59 of 144 individuals (41.0%). Twenty-one sputum tests
were conducted on the 18 sputum samples collected. Posi-
tive results were seen in one of four sputum samples
(25.0%) sent for TB microscopy, 6 of 15 (40.0%) sent for
Xpert MTB/RIF testing; and in one of two (50.0%) sent for
mycobacterial culture. No mycobacterial blood cultures
were performed. Of the 57 admissions for whom at least one
WHO TB symptom was documented, sputum was collected
12 of 57 times (21.1%), and a chest radiograph was con-
ducted 37 of 57 times (64.9%). Selected characteristics for
those who had sputum collected or had a chest radiograph
while hospitalized are described in Supplemental Table S7.
Management of TB and HIV as an inpatient. In 102 of
304 admissions (33.6%), the individual was not on ART at the
time of admission. In 7 of 102 admissions (6.9%), ART was ini-
tiated as an in-patient. In 48 of 102 admissions (47.1%), ART
was deferred because there were concomitant reasons not to
initiate ART. However, in 47 of 102 admissions (46.1%), ART
was not initiated and potential reasons for deferral were not
recorded. In 19 of 47 of these instances (40.4%), the individual
was referred to a local clinic to start ART.
Anti-TB treatment was initiated during 38 admissions. In
24 of 38 admissions (63.2%), one or more WHO TB symp-
tom had been recorded, and in 9 of 38 admissions (22.5%) a
sputum-based investigation had been conducted. Empirical
anti-TB treatment (without a positive sputum result) was initi-
ated on 32 of 38 occasions (84.2%).
DISCUSSION
In the context of a pragmatic trial that recruited ambulatory
adults with advanced HIV attending PHC clinics in South
Africa, we used a wide range of data and a structured and
transparent process to examine 304 admissions in 251 individ-
uals, and described causes for admission, mortality, and
investigation for TB. More than one third of admissions were
TB related. Overall mortality was very high: 55% of individuals
in this analysis (median age, 39 years) died in hospital or within
90 days of discharge from their first admission. Of those
admitted with TB, bacterial infections, or renal or liver failure,
the proportion who died was 65% or more. TB was generally
under-investigated. Sputum-based investigations were used
in only 21% of those with at least one recorded WHO TB
symptom. Our findings underline the need for improvements
along the care pathway for adults with advanced HIV, from
community clinics and in-hospital management to post-
discharge follow-up, to ensure more timely referral to second-
ary care, greater awareness and appropriate investigation for
TB among inpatients, and prompt initiation of ART.24
Our most striking finding is the high mortality rate associ-
ated with admission. All those included in this analysis
attended a PHC clinic and were identified as HIV-positive a
median of 40 days prior to admission, which presented a
window of opportunity for clinical support. The WHO recom-
mends a “package of interventions” to reduce HIV-
associated morbidity and mortality that includes the need for
early identification of HIV,1 screening for opportunistic infec-
tions, appropriate prophylaxis, and initiation of ART through
a test-and-treat strategy.25 Prompt ART initiation was
strongly encouraged in the intervention arm of this pragmatic
TABLE 3




Probability of cause,* n (row %)
Definite Probable Possible
Total 251 82 (32.7) 87 (34.7) 82 (32.7)
AIDS-related illness* 41 (16.3) 29 (70.7) 4 (9.8) 8 (19.5)
Previously undiagnosed TB 52 (20.7) 11 (21.2) 28 (53.9) 13 (25.0)
On TB treatment with worsening TB disease 43 (17.1) 9 (20.9) 11 (25.6) 23 (53.5)
Surgical 21 (8.4) 12 (57.1) 6 (28.6) 3 (14.3)
Treatment related 18 (7.2) 0 13 (72.2) 5 (27.8)
Bacterial infection 20 (8.0) 5 (25.0) 6 (30.0) 9 (45.0)
Non-communicable disease 14 (5.6) 10 (71.4) 2 (14.3) 2 (14.3)
Gastrointestinal disorders 12 (4.8) 0 3 (25.0) 9 (75.0)
Liver/renal failure 9 (3.6) 1 (11.1) 7 (77.8) 1 (11.1)
Neurological disorder 5 (2.0) 0 3 (60.0) 2 (40.0)
Hematological disorder 7 (2.8) 3 (42.9) 3 (42.9) 1 (14.3)
Unknown 6 (2.4) 0 0 6 (100)
Psychiatric disorder 3 (1.2) 2 (66.6) 1 (33.3) 0
TB5 tuberculosis.
* See Supplemental Table S1 for criteria used to assign causes and probabilities.
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trial, however clinical decisions were made by clinic staff. In
our analysis, only 60% of individuals were on ART at the
time of their first admission, and ART was initiated as an
inpatient for seven others. Along with strategies to improve
access to care and expand HIV testing,26 more regular
engagement with patients by PHC clinics during and after
ART initiation may be beneficial in detecting warning signs
and enabling earlier referral to a hospital.
The post-discharge period is also high risk. Other studies
in South Africa have shown that mortality at 90 days post-
discharge for HIV-positive adults ranges from 13% to
26%.27,28 In our analysis, 26% of individuals died within 90
days of their first discharge (15 as inpatients during a subse-
quent admission), and 13% of those discharged were read-
mitted within 30 days. Strengthening processes for ensuring
clear communication and handover to primary or community
care may help to reduce readmission rates and improve
outcomes.29
Our study shows that an important part of in-hospital man-
agement of adults with advanced HIV relies on having a high
TABLE 4
Selected characteristics of adults with advanced HIV admitted to hospital within 1 year of enrollment, cross-referenced with
research-assigned cause of first admission (N 5 251)
Characteristic
Total, n (%) or
median (IQR)














Total 251 41 52 43 21 18 20 12 9 35
Age group (y)
18–23 6 (2.4) 2 (4.9) 1 (1.9) 2 (4.7) 1 (4.8) 0 0 0 0 0
24–33 70 (27.9) 9 (22.0) 21 (40.4) 11 (25.6) 7 (33.3) 7 (38.9) 2(10.0) 5 (41.7) 1 (11.1) 7 (20.0)
34–43 106 (42.2) 17 (41.5) 24 (46.2) 15 (34.9) 10 (47.6) 7 (38.9) 8 (40.0) 3 (25.0) 4 (44.4) 18 (51.4)
44–60 61 (24.3) 10 (24.4) 6 (11.5) 14 (32.6) 3 (14.3) 4 (22.2) 9 (45.0) 4 (33.3) 3 (33.3) 8 (22.9)
. 60 8 (3.2) 3 (7.3) 0 1 (2.3) 0 0 1 0 1 (11.1) 2 (5.7)






145 (57.8) 29 (70.7) 16 (30.8) 30(69.8) 14 (66.7) 12 (66.7) 11 (55.0) 7 (58.3) 3 (33.3) 23 (65.7)
CD4 count at enrollment to TB Fast Track trial (cells/mL)
#50 132 (52.6) 27 (65.9) 31 (59.6) 25 (58.1) 6 (28.6) 11 (61.1) 5 (25.0) 6 (50.0) 3 (33.3) 18 (51.4)
51–100 80 (31.9) 11 (26.8) 10 (19.2) 13 (30.2) 9 (42.9) 4 (22.2) 11 (55.0) 4 (33.3) 5 (55.6) 13 (37.1)
101–150 39 (15.5) 3 (7.3) 11 (21.2) 5 (11.6) 6 (28.6) 3 (16.7) 4 (20.0) 2 (16.7) 1 (11.1) 4 (11.4)
Time from enrollment to admission (d)
# 7 30 (12.0) 6 (14.6) 9 (17.3) 8 (18.6) 0 0 0 0 0 7 (20.0)
8–28 69 (27.5) 19 (46.3) 13 (25.0) 8 (18.6) 5 (23.8) 9 (50.0) 5 (25.0) 2 (16.7) 1 (11.1) 7 (20.0)
29–90 76 (30.3) 7 (17.1) 21 (40.4) 11 (25.6) 5 (23.8) 6 (33.3) 5 (25.0) 3 (25.0) 4 (44.4) 14 (40.0)
91–180 51 (20.3) 4 (9.8) 7 (13.5) 11 (25.6) 8 (38.1) 2 (11.1) 8 (40.0) 4 (33.3) 2 (22.2) 5 (14.3)
181–365 25 (10.0) 5 (12.2) 2 (3.9) 5 (11.6) 3 (14.3) 1 (5.6) 2(10.0) 3 (25.0) 2 (22.2) 2 (5.7)
On ART at
admission


















eGFR at admission (mL/min/1.73 m2)
# 30 60 (29.1) 8 (21.6) 14 (31.1) 11 (29.7) 2 (14.3) 3 (21.4) 7 (41.2) 3 (42.9) 9 (100.0) 3 (11.5)
31–60 25 (12.1) 3 (8.1) 8 (17.8) 4 (10.8) 2 (14.3) 3 (21.4) 2 (11.7) 1 (14.3) 0 2 (7.7)
61–90 37 (18.0) 6 (16.2) 9 (20.0) 6 (16.2) 4 (28.6) 3 (21.4) 3 (17.6) 1 (14.3) 0 5 (19.2)




223 35 49 40 17 16 17 11 9 29
Hb at admission (g/dL)
, 7.0 51 (22.8) 5 (14.3) 15 (30.6) 6 (15.0) 2 (11.8) 1 (6.3) 8 (47.1) 1 (9.1) 4 (44.4) 9 (31.0)
7.0–8.9 50 (22.4) 8 (22.9) 12 (24.5) 13 (32.5) 3 (17.7) 1 (6.3) 5 (29.4) 3 (27.3) 3 (33.3) 2 (6.9)
9.0–10.9 56 (25.1) 9 (25.7) 9 (18.4) 11(27.5) 4 (23.5) 6 (37.5) 4 (23.5) 3 (27.3) 1 (11.1) 9 (31.0)
11.0–12.9 47 (21.1) 12 (34.3) 8 (16.3) 9 (22.5) 6 (35.3) 6 (37.5) 0 2 (18.2) 1 (11.1) 3 (10.3)
$ 13.0 19 (8.5) 1 5 (10.2) 1 (2.5) 2 (11.8) 2 (12.5) 0 2 (18.2) 0 6 (20.7)
ART5 antiretroviral therapy; eGFR5 estimated glomerular filtration rate; Hb5 hemoglobin; IQR5 interquartile range; TB5 tuberculosis.
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level of suspicion for infection-related illnesses (TB, bacte-
rial, and other AIDS-related illnesses), which are still the
most common causes of admission for HIV-positive adults
in this setting.3,10,27 We estimated that one third of
admissions in our analysis were TB related. TB has been
shown to account for 18% to 33% of hospital admissions
among HIV-positive adults in similar settings.10,14,27 Even
with a high suspicion for TB, making a timely diagnosis is
Started an-TB treatment in hospital (n = 24 ) Started an-TB treatment in hospital (n = 14)
251 individuals experienced 304 admissions 
aer enrolment to “TB Fast Track”
No WHO TB symptoms* recorded
87 admissions
≥1 WHO TB symptom* recorded
57 admissions
Already on an-TB 
treatment
160 admissions


































Microbiological confirmaon of TB (n=5) Microbiological confirmaon of TB (n=2)
4 0 01 2 0 0  0
FIGURE 3. Tuberculosis (TB) diagnostics performed on admissions not on anti-TB treatment (n 5 144) comparing symptomatic (n 5 57) and
asymptomatic (n5 87) admissions. Cul 5 TB culture; CXR5 chest X-ray; GXP5 Xpert MTB/RIF assay; Ix 5 investigations; micro5 microscopy;












































Research-assigned cause of admission
Death in hospital Death within 90 days of discharge Alive 90 days aer discharge
FIGURE 2. Outcome of first admission by cause of admission (N5 251). TB5 tuberculosis; tx5 treatment.
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difficult because of the limitations of the available investiga-
tions, many of which are less sensitive in people with low
CD4 counts. However, we found that even the use of TB
investigations was limited. Sputum tests for TB were per-
formed in only 12.5% of admissions, regardless of present-
ing complaint, and in 21.1% of those who reported one or
more WHO TB symptom. Others have shown that TB spu-
tum tests may be underused because very ill HIV-positive
adults are unable to produce sputum as a result of their ill-
ness,14 because clinicians may not suspect TB as a result of
the atypical presentation of the disease in adults with
advanced HIV,14 and because clinicians in these settings
may see little advantage in performing sputum investigations
when the diagnosis can be made clinically or radiologi-
cally.30,31 However, despite the reduced sensitivity of spu-
tum Xpert MTB/RIF testing in HIV-positive adults,32 part of
its utility at the population level comes from its consistent
use in those at high risk of TB. Therefore, the underuse
documented in this study represents a missed opportunity
to maximize the overall number of TB diagnoses made.
Disseminated TB in adults with advanced HIV may also be
missed by an algorithm that is reliant on sputum investiga-
tions.33 A recent meta-analysis found that the detection of
TB bloodstream infection in adults with advanced HIV
increased from 77% (95% CI, 63–87%) when only sputum
investigations were used, to 89% (95% CI, 80–94%) when
used in combination with the urine LAM test.34 The use of
urine LAM with subsequent initiation of anti-TB treatment
has been shown to reduce mortality in hospitalized adults
with advanced HIV,35 although its inability to detect drug-
resistant TB may limit its utility.36 Because of the high
prevalence of TB in this population, and the extremely high
mortality associated with it,37 intensive use of imaging and
all available TB tests on both respiratory and non-respiratory
specimens may be needed in all hospitalized adults with
advanced HIV regardless of presenting symptoms.14,34 Fur-
thermore, as autopsy studies have demonstrated, multiple
concomitant pathologies may be present along with TB.
Packages of care for these individuals should include appro-
priate investigation, prophylaxis, and treatment of other
infections and malignancies in addition to TB.
This article considers only a small proportion of the individu-
als enrolled in the TB Fast Track trial, but our findings may
help explain the results of the trial, which found that the use of
empirical TB treatment, guided by a novel, point-of-care algo-
rithm, did not reduce mortality in ambulatory adults with
advanced HIV. Our analysis shows the variety of conditions,
including bacterial infections and AIDS-defining illnesses, that
contribute to morbidity and mortality in this group. It is worth
noting that among those in this analysis with “previously
undiagnosed TB,” mortality was around 50% for those who
were not started on TB treatment as inpatients, but was also
around 50% for those who were started on TB treatment.
Identifying and treating TB, although clearly important, is
unlikely to be the only intervention needed in people with
advanced HIV disease. Pragmatic trials of alternative strate-
gies, including packages of care and systems-level interven-
tions to identify and engage people earlier in the illness
trajectory,38 are urgently needed to reduce the numbers of
preventable deaths seen in these vulnerable individuals.
Limitations and strengths. Our analysis was based on a
single reviewer’s categorization of admissions; but, to
delineate the quality of evidence and likelihood of diagnosis,
a probability was allocated for each admission, and 20% of
cases were blind-reviewed to validate the initial allocations.
This was also a retrospective study. When allocating causes
of admission, there was a reliance on the investigations per-
formed, accurate documentation of symptoms and signs,
and attending clinicians’ interpretations of imaging. Gaps in
the available data meant that a high proportion (66%) of
research-assigned causes of admission were assigned with
only a “possible” or “probable” likelihood; and broad,
system-based “syndromes” were used when information
was not sufficient even to estimate a more specific category.
Our findings and conclusions should be interpreted in the
context of this uncertainty. Only the most likely cause of
admission was assigned for each admission, which may
have underestimated the proportion of individuals with multi-
ple pathology at the time of admission. In the TB Fast Track
autopsy sub-study (n534), around 60% of those autopsied
had evidence of two or more concurrent infections.39 These
results also need to be considered in the context of the par-
ent trial;18 the intervention increased the number of persons
admitted on TB treatment, which would have decreased the
number of admissions with previously undiagnosed TB and
underestimated the extent to which TB treatment was initi-
ated in the hospital. Hospitalization was also likely under-
ascertained in control clinics because fewer study visits
were required and participants likely had less interaction
with research and clinic staff. Admissions included in this
analysis took place between 2013 and 2015 and may not be
reflective of current practice in the hospitals included. How-
ever, South African national guidelines for the investigation
and treatment of TB have not changed substantially in the
intervening time,20 and studies reporting more recent data
also show considerable TB-related morbidity and mortality
in hospitalized individuals with advanced HIV. Two thirds of
admissions were identified because the individual was
known to have died, which may have led to overestimation
of the overall case fatality rate. This study’s strengths include
the examination of the course of illness and clinical manage-
ment of a well-defined group of individuals for the full length
of admission, and use of a transparent and reproducible
method to assign causes of admission, linking these to high-
quality information on mortality.
CONCLUSION
Hospitalized adults with advanced HIV are at high risk of
death. TB was a common cause of hospitalization but was
under-investigated, even in those with symptoms. In addi-
tion to early identification of TB and other AIDS-related ill-
nesses during hospitalization of adults with advanced HIV,
improved pre-hospital management strategies are needed
to interrupt disease progression and reduce poor outcomes
in this already vulnerable population.
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